Typhoid Vi Polysaccharide Vaccine Market Report 2026

The typhoid vi polysaccharide vaccine market size has grown rapidly in recent years. It will grow from $6.71 billion in 2025 to $7.92 billion in 2026 at a compound annual growth rate (CAGR) of 18.1%. The growth in the historic period can be attributed to expansion of national immunization schedules, increased awareness of typhoid prevention, availability of polysaccharide vaccine formulations, growth of public vaccination campaigns, support from global health organizations.

The typhoid vi polysaccharide vaccine market size is expected to see rapid growth in the next few years. It will grow to $15.51 billion in 2030 at a compound annual growth rate (CAGR) of 18.3%. The growth in the forecast period can be attributed to increasing focus on mass immunization in endemic regions, rising investments in vaccine manufacturing capacity, expansion of adult vaccination programs, growing emphasis on travel-related immunization, increasing adoption of improved vaccine storage technologies. Major trends in the forecast period include increasing government-led immunization programs, rising demand for pediatric vaccination coverage, growing focus on preventive healthcare measures, expansion of public-private vaccine distribution models, enhanced emphasis on cold chain optimization.

The increasing prevalence of typhoid is expected to drive the growth of the typhoid Vi polysaccharide vaccine market going forward. Typhoid is an infection caused by Salmonella Typhi, which can be fatal and is typically transmitted through contaminated food or water. Factors such as poor sanitation, unsafe water sources, rapid urbanization, and higher exposure to contaminated food and water contribute to the rising prevalence of typhoid. The typhoid Vi polysaccharide vaccine market addresses this need by providing immunization for adults and children aged 2 years and older, offering protective immunity against Salmonella enterica serovar Typhi and reducing the burden of typhoid fever in endemic areas. For example, in August 2024, according to the UK Health Security Agency, laboratory-confirmed symptomatic enteric fever cases in England, Wales, and Northern Ireland increased, with S. Typhi reaching 313 cases, S. Paratyphi A reaching 135 cases, and S. Paratyphi B reaching 18 cases. Therefore, the rising prevalence of typhoid is propelling the growth of the typhoid Vi polysaccharide vaccine market.

Expanding immunization campaigns are expected to further support the growth of the typhoid Vi polysaccharide vaccine market. Immunization campaigns are strategies designed to rapidly reach large populations with one or more vaccines at national or sub-national levels. The growth of these campaigns is driven by heightened public health focus on typhoid prevention in high-burden regions and the need to reduce antimicrobial resistance through widespread vaccination. These campaigns enhance the typhoid Vi polysaccharide vaccine market by increasing awareness, accessibility, and coverage, ultimately reducing typhoid incidence and transmission. For instance, in June 2023, according to the UK Health Security Agency, a total of 3,502,566 children from Reception to Year 9 were vaccinated as part of the school-aged vaccination program in 2022-2023. Therefore, the expansion of immunization campaigns is driving the growth of the typhoid Vi polysaccharide vaccine market.

Key companies in the typhoid Vi polysaccharide vaccine market are focusing on strengthening their position through strategic investments and collaborative initiatives, such as funding partnerships for next-generation vaccine delivery platforms, to accelerate innovation and expand global immunization reach. These partnerships aim to develop improved typhoid vaccination technologies, including needle-free, thermostable, and easy-to-administer formats that enhance accessibility, coverage, and compliance in low-resource settings. For example, in August 2023, SK Bioscience, a South Korea-based biotech company, together with Vaxxas, an Australia-based biotechnology firm specializing in needle-free vaccine delivery, secured AUD 0.0054 billion (USD 0.00367 billion) in funding from Wellcome, a UK-based charitable foundation, to develop a typhoid conjugate vaccine delivered via a needle-free high-density microarray patch (HD-MAP). This innovation features a micro-projection patch that eliminates traditional needles, offers thermostability for distribution in low-infrastructure regions, and allows for simplified, pain-free administration, targeting improved global uptake of typhoid vaccination.

Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., Merck & Co. Inc., PT Bio Farma, Bharat Biotech International Limited, Bio-Med Pvt. Ltd., Hualan Biological Engineering Inc., Indian Immunologicals Limited, Serum Institute of India Limited, Biological E Limited, Panacea Biotec Limited, Zydus Lifesciences Limited, Beijing Minhai Biotechnology Co. Ltd., Lanzhou Institute of Biological Products Co. Ltd., Chengdu Institute of Biological Products Co. Ltd., Wuhan Institute of Biological Products Co. Ltd., Eubiologics Co. Ltd., Incepta Vaccine Limited, GC Pharma, KM Biologics Inc., Bharat Immunologicals and Biologicals Corporation Limited, Sinovac Biotech Ltd., Bio Farma Indonesia.

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2025. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the typhoid vi polysaccharide vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the typhoid vi polysaccharide vaccine market by increasing costs of imported raw materials, vials, syringes, cold-chain equipment, and pharmaceutical manufacturing inputs. Vaccine producers and public health agencies in Asia-Pacific and Africa are most affected due to dependence on international supply chains, while Europe and North America face higher packaging and logistics costs. These tariffs are increasing program costs and affecting rollout timelines. However, they are also encouraging local vaccine production, regional fill-and-finish facilities, and strengthened domestic vaccine supply chains.

The typhoid vi polysaccharide vaccine market research report is one of a series of new reports that provides typhoid vi polysaccharide vaccine market statistics, including typhoid vi polysaccharide vaccine industry global market size, regional shares, competitors with a typhoid vi polysaccharide vaccine market share, detailed typhoid vi polysaccharide vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the typhoid vi polysaccharide vaccine industry. This typhoid vi polysaccharide vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Typhoid Vi polysaccharide vaccine refers to the recommended active immunization for individuals aged two years and above to prevent typhoid fever caused by Salmonella Typhi.

The primary types of typhoid Vi polysaccharide vaccines are for children and adults. A child is defined as a person from birth to puberty or full growth. The vaccine can be administered via oral or parenteral routes and is used in settings such as government institutions, the private sector, and others.

The typhoid Vi polysaccharide vaccine market consists of sales of Vi capsular polysaccharide vaccine, and non-conjugated Vi polysaccharide vaccine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.